Gold has topped $4,200. Here’s why Yardeni thinks the rally could go even higher.
Ligand Pharmaceuticals Incorporated stock reached a 52-week high, hitting $172.49. This milestone reflects a significant upward trajectory for the company over the past year, with analysts setting price targets ranging from $164 to $206. According to InvestingPro analysis, the company maintains strong financial health with a current ratio of 5.45, indicating robust liquidity. The stock has seen a remarkable 71.54% increase in its value over the last 12 months, underscoring investor confidence and positive market sentiment. With revenue growth of 40.54% and analysts expecting profitability this year, Ligand Pharmaceuticals, a company known for its innovative approaches in drug discovery and development, has continued to capture the attention of market participants. InvestingPro subscribers can access 10+ additional investment tips and comprehensive analysis in the Pro Research Report, essential for understanding the complete investment picture.
In other recent news, Ligand Pharmaceuticals has completed a significant financial maneuver by raising $460 million through a convertible notes offering, with net proceeds amounting to approximately $445.1 million after deducting fees and expenses. This capital raise has influenced several analysts to adjust their price targets for the company. Oppenheimer increased its price target to $190, citing the successful mid-August capital raise and maintaining an Outperform rating. Similarly, Benchmark raised its price target to $175, highlighting Ligand’s strong second-quarter 2025 earnings report as a key factor. H.C. Wainwright also raised its price target to $206, following the FDA’s approval of an update to the REMS labeling for FILSPARI, which included reduced liver function monitoring and the removal of pregnancy monitoring requirements. These developments reflect a positive outlook from analysts regarding Ligand’s recent financial and regulatory achievements.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.